Literature DB >> 19166693

Ten-year all-cause mortality in presumably healthy subjects on lipid-lowering drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort).

Virginie Gardette1, Vanina Bongard, Jean Dallongeville, Dominique Arveiler, Annie Bingham, Jean-Bernard Ruidavets, Philippe Amouyel, Bernadette Haas, Pierre Ducimetière, Jean Ferrières.   

Abstract

Lipid-lowering drugs are one of the most prescribed drugs worldwide. The aim was to compare 10-year all-cause mortality according to initial dyslipidemia status and lipid-lowering drug exposure. The PRIME study was a multicenter population-based prospective cohort study of men recruited in 1991 to 1993, aged 50 to 59 years at baseline, and followed up for 10 years. The 4 groups compared were normolipidemic, untreated dyslipidemic, and dyslipidemic subjects on fibrate or statin therapy. Data were analyzed using multivariate Cox models. The cohort included 7,722 French men (statin group 4.0%, fibrate group 7.9%, untreated dyslipidemic subjects 19.0%, and normolipidemic subjects 69.1%). After 10 years, 4.8% of the sample was lost to follow-up and 416 deaths occurred (cancers 53.1%, cardiovascular diseases 17.1%, and other 29.8%). After adjustment for center, age, educational level, cardiovascular risk factors, lipids, alcohol intake, and history of cardiovascular and severe chronic diseases, hazard ratios (HRs) for all-cause mortality were 0.49 (95% confidence interval [CI] 0.26 to 0.94, p = 0.031) for subjects treated with a statin, 0.65 (95% CI 0.42 to 0.99, p = 0.046) for those on fibrate therapy, and 0.76 (95% CI 0.56 to 1.03, p = 0.080) for normolipidemic men compared with untreated dyslipidemic subjects. In the statin group, HRs for death from cardiovascular disease, cancer, and other causes were 0.55 (p = 0.348), 0.41 (p = 0.067), and 0.68 (p = 0.546) compared with dyslipidemic subjects, respectively. In the fibrate group, HRs were 0.76 (p = 0.499), 0.52 (p = 0.041), and 0.87 (p = 0.746). In conclusion, in this cohort study carried out in a real-life setting, all-cause mortality was significantly lower in dyslipidemic subjects on fibrate or statin therapy than in untreated dyslipidemic patients. No excess risk of noncardiovascular death was observed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19166693     DOI: 10.1016/j.amjcard.2008.09.092

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

Review 1.  Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins.

Authors:  Goodarz Danaei; Mohammad Tavakkoli; Miguel A Hernán
Journal:  Am J Epidemiol       Date:  2012-01-05       Impact factor: 4.897

2.  Fenofibrate-induced nuclear translocation of FoxO3A triggers Bim-mediated apoptosis in glioblastoma cells in vitro.

Authors:  Anna Wilk; Katarzyna Urbanska; Maja Grabacka; Jennifer Mullinax; Cezary Marcinkiewicz; David Impastato; John J Estrada; Krzysztof Reiss
Journal:  Cell Cycle       Date:  2012-07-15       Impact factor: 4.534

3.  Molecular mechanisms of fenofibrate-induced metabolic catastrophe and glioblastoma cell death.

Authors:  Anna Wilk; Dorota Wyczechowska; Adriana Zapata; Matthew Dean; Jennifer Mullinax; Luis Marrero; Christopher Parsons; Francesca Peruzzi; Frank Culicchia; Augusto Ochoa; Maja Grabacka; Krzysztof Reiss
Journal:  Mol Cell Biol       Date:  2014-10-20       Impact factor: 4.272

Review 4.  Peroxisome proliferator activated receptor α ligands as anticancer drugs targeting mitochondrial metabolism.

Authors:  Maja Grabacka; Malgorzata Pierzchalska; Krzysztof Reiss
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

5.  PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARα/AMPK/AKT/FoxO1 pathway.

Authors:  Mei-Sa Wang; Qiu-Shuang Han; Zhi-Rong Jia; Chuan-Sheng Chen; Chen Qiao; Qian-Qian Liu; Ya-Meng Zhang; Kai-Wei Wang; Jie Wang; Kang Xiao; Xuan-Sheng Ding
Journal:  Acta Pharmacol Sin       Date:  2021-03-26       Impact factor: 7.169

Review 6.  Gene activation regresses atherosclerosis, promotes health, and enhances longevity.

Authors:  Pauli V Luoma
Journal:  Lipids Health Dis       Date:  2010-07-06       Impact factor: 3.876

7.  Fibrates and risk of cancer in tissues with high PPAR-α concentration: a nested case-control study.

Authors:  Francesco Salvo; Fabienne Bazin; Aude Kostrzewa; Christian Bandre; Philip Robinson; Nicholas Moore; Bernard Bégaud; Antoine Pariente
Journal:  Drug Saf       Date:  2014-05       Impact factor: 5.606

8.  Fenofibrate-induced mitochondrial dysfunction and metabolic reprogramming reversal: the anti-tumor effects in gastric carcinoma cells mediated by the PPAR pathway.

Authors:  Lulu Chen; Jin Peng; You Wang; Huangang Jiang; Wenbo Wang; Jing Dai; Meng Tang; Yan Wei; Hao Kuang; Guozeng Xu; Hui Xu; Fuxiang Zhou
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

Review 9.  Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trials.

Authors:  Stefanos Bonovas; Georgios K Nikolopoulos; Pantelis G Bagos
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

10.  A prospective study of statin use and mortality among 67,385 blacks and whites in the Southeastern United States.

Authors:  Loren Lipworth; Sergio Fazio; Edmond K Kabagambe; Heather M Munro; Victor C Nwazue; Robert E Tarone; Joseph K McLaughlin; William J Blot; Uchechukwu Ka Sampson
Journal:  Clin Epidemiol       Date:  2013-12-19       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.